|
|
Raising the Bar on Obesity Management in Psoriasis and Psoriatic Arthritis: A Collaborative Learning Experience for Dermatology and Rheumatology Healthcare Professionals
2025 AANP National Conference
|
|
Facebook
LinkedIn
E-Mail
|
(3430)
|
Released: 07/01/2025
Expires: 07/31/2026 (subject to change)
- CE for this activity will not be available after this date.
 | This activity includes closed captioning. |
| Delivery Note: The content for this activity was presented during the 2025 AANP National Conference. If you already completed the content of this activity (session ID 25.3.132) while attending the live or virtual conference, you should not complete this content a second time. Learners should only complete ONE delivery-method to earn credit. Completing multiple delivery options for the same activity is considered duplicate credit for the same content and will not be accepted by regulatory bodies. |
Overview
This interdisciplinary course explores the intricate relationship between obesity and psoriatic disease, emphasizing the bidirectional role of systemic inflammation. Led by a panel of experts in dermatology, rheumatology, and obesity medicine, participants will gain a deeper understanding of the pathophysiological crosstalk between adiposity and psoriatic inflammation, the impact of obesity on disease severity and treatment outcomes, and evidence-based strategies for screening, counseling, and management. Learners will review clinical cases, explore current pharmacologic and lifestyle interventions—including anti-obesity medications—and receive practical guidance on engaging in sensitive, patient-centered conversations. Designed for nurse practitioners, the course reinforces the importance of a multidisciplinary, empathetic, and evidence-informed approach to improve outcomes for patients with psoriatic disease.
Objectives
- Evaluate the evidence for the correlation between PsO, PsA, and obesity, including obesity-associated comorbidities.
- Implement recommended screening and management practices for obesity in patients with PsO and/or PsA.
- Apply expert guidance to have clear, yet compassionate and culturally sensitive conversations with patients around weight and metabolic health.
- Integrate collaborative patient goals and preferences into management plans for patients with PsO/PsA and obesity.
Speakers
Veronica Richardson, MSN, ANP-BC, DCNP
Philip Mease, MD, MACR
Daniel C. Butler, MD
Disclosure
This program was planned in accordance with AANP CE Standards and Policies.
The speakers have the following disclosures: - Philip Mease, MD, MACR:
- Consultant: AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Cullinan Biotech, Inmagene, Janssen, Lilly, MoonLake, Novartis, Pfizer, Takeda, UCB;
- Researcher: AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, UCB;
- Data and safety monitoring board: Genascence;
- Speaker: AbbVie, Amgen, Janssen, Lilly, Pfizer, UCB
- Daniel C. Butler, MD:
- Consultant/advisor/speaker: Galderma, Leo Pharma, Sanofi
- Veronica Richardson, MSN, ANP-BC, DCNP:
- Advisor: Bristol Meyers Squibb, Dermavant Science, Leo, Lilly, Sanofi-Regeneron
- April W. Armstrong, MD, MPH:
- Researcher: AbbVie, ASLAN, Bristol Myers Squibb, Dermavant Sciences, Dermira, Galderma, Incyte, Janssen, Leo Pharma, Lilly, Meiji, Nimbus, Novartis, Ortho Derm, Pfizer, Sanofi, UCB, Ventyx;
- Consultant/advisor/speaker: AbbVie, ASLAN, Almirall, Amgen, Arcuits, Beiersdorf, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Janssen, Leo Pharma, Lilly, Mindera, Novartis, Organon & Co, Regeneron, Sanofi, Sun Pharma, Takeda, UCB, Ventyx;
- Data and safety monitoring board: Boehringer Ingelheim, Parexel
- Carolynn Francavilla, MD, FOMA, D-ABOM:
- Consultant/advisor/speaker: Lilly;
- Individual publicly traded stock/stock options: Lilly, Novo Nordisk
Planners from CEA/CCO and AANP have no disclosures.
This activity is supported by an educational grant from Lilly.
Disclaimer
Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions- Read this activity description, including objectives and disclosures.
- Take pretest.
- Complete the educational content:
- Video Presentations: Click the Play button to watch the activity presentation. Full participation credit for the activity will be received once the entire video has been watched.
- Click on the Additional Resources button to review all additional materials provided (slide handouts and any other downloadable resources).
- After completing all content, click on the blue Next Steps button:
- Take post-test.
- Submit the evaluation to receive full AANP CE/Rx credit.
Additional Information
For questions or more information concerning this online CE activity, please visit the AANP Help Center to find answers to frequently asked questions and request assistance.
1.25 Contact Hour(s) of CE,
0.5 of which may be applied towards Pharmacology
|
|
|
|
Adding Registration, Please wait...
